Skip to main content
Fig. 5 | BMC Proceedings

Fig. 5

From: The use of the CNIC-Polypill in real-life clinical practice: opportunities and challenges in patients at very high risk of atherosclerotic cardiovascular disease – expert panel meeting report

Fig. 5

The algorithm shows the steps and options to switch patients treated for chronic coronary syndromes to the CNIC-Polypill strategy. Note: The coloured balls represent the appropriate formulation of the CNIC-Polypill according to the coloured lines of the algorithm. *Dose adjusted to BP levels, previous ACEI/ARB dose and renal function. **See above for additional treatment of high LDL-c levels. $Use only if the patient does not develop side effects to atorvastatin 80 mg (or equivalent doses of another statin). †If the combination is available. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; AT, atorvastatin; BP, blood pressure; CCB, calcium channel blocker; CCS, chronic coronary syndrome; EZE, ezetimibe; FDC, fixed-dose combination; LDL-c, low-density lipoprotein cholesterol; PAD, peripheral artery disease; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor; RAM, ramipril; Tx, treatment. Source: Grigorian-Shamagian et al. Front Cardiovasc Med. 2021;8:663,361 [12]. Reproduced with permission

Back to article page

BMC Proceedings

ISSN: 1753-6561

Contact us